Max Rosett

Direttore Finanziario/CFO presso IMMUNOME, INC.

Patrimonio netto: 296 649 $ in data 31/05/2024

34 anni

100 relazioni

Health Technology

Consumer Services

Finance

Profilo

Max Rosett is currently working as the CFO, Chief Accounting Officer & EVP-Operations at Immunome, Inc. He previously worked as the Chief Operating Officer at MorphImmune, Inc. from 2022 to 2023 and as a Principal at Research Bridge Partners from 2018 to 2023.
Mr. Rosett graduated from the Georgia Institute of Technology in 2016 with a graduate degree and from Yale University in 2012 with an undergraduate degree.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
IMMUNOME, INC. 0.03%	16/05/2024	19 856 ( 0.03% )	296 649 $	31/05/2024

Posizioni attive di Max Rosett

Società	Posizione	Inizio
IMMUNOME, INC.	Direttore Finanziario/CFO	02/01/2024

Tutte le posizioni attive di Max Rosett

Precedenti posizioni note di Max Rosett

Società	Posizione	Fine
Research Bridge Partners /Venture Capital/ Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas.	Corporate Officer/Principal	01/11/2023
MorphImmune, Inc. MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.	Direttore operativo	01/10/2023

Vedi nel dettaglio l'esperienza di Max Rosett

Formazione di Max Rosett

Yale University	Undergraduate Degree
Georgia Institute of Technology	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Max Rosett

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
IMMUNOME, INC.	Health Technology

Aziende private	2
MorphImmune, Inc. MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.	Health Technology
Research Bridge Partners /Venture Capital/ Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas.	Finance